Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.86 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15653554 | 0.94 | MAPK1 (0.76) | MAPK1ALK | |
| SCHEMBL15652538 | 0.92 | MAPK1 (1.00) | MAPK1ALKL3MBTL1MKNK1 | |
| SCHEMBL15652056 | 0.92 | MAPK1 (0.76) | MAPK1ALKL3MBTL1 | |
| SCHEMBL15653479 | 0.89 | MAPK1 (0.79) | MAPK1ALKMKNK1 | |
| SCHEMBL15652637 | 0.89 | MAPK1 (0.79) | MAPK1ALKL3MBTL1MKNK1 | |
| SCHEMBL15653094 | 0.89 | MAPK1 (0.79) | MAPK1ALKPIK3CD | |
| SCHEMBL15654007 | 0.87 | MAPK1 (0.70) | MAPK1ALKMKNK1 | |
| SCHEMBL15607460 | 0.87 | MAPK1 (0.70) | MAPK1ALK | |
| SCHEMBL15653225 | 0.87 | MAPK1 (0.69) | MAPK1ALKL3MBTL1PIK3CD | |
| SCHEMBL15653713 | 0.87 | MAPK1 (0.69) | MAPK1ALKL3MBTL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382257-B2 | Substituted pyrrolo[2,3-b]pyrazines as serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150218176-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218176-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | MAPK1 29/4885ALK 896/4885L3MBTL1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.